FBP2 and sarcoma: Furthermore, FBP2 overexpression inhibits sarcoma cell growth [13], VLDLR overexpression inhibits CC cell proliferation and migration [14], OGDHL silencing contributes to the survival of HCC patients via the regulation of glutamine metabolic pathways [15], and IDH1 mutation promotes glioma cell proliferation and migration via EMT [16].